Open AccessS0819 Evaluating Cost Per Remission and Cost of Serious Adverse Events in Advanced Therapies for Ulcerative Colitis
Author(s) -
Vipul Jairath,
Russell D. Cohen,
Edward V. Loftus,
Ninfa Candela,
Karen Lasch,
Bob Schultz
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000705324.95048.a6
Subject(s) - medicine , vedolizumab , adalimumab , ulcerative colitis , infliximab , number needed to treat , adverse effect , tofacitinib , number needed to harm , population , golimumab , regimen , surgery , confidence interval , relative risk , rheumatoid arthritis , tumor necrosis factor alpha , disease , environmental health